Cullen Capital Management LLC lessened its stake in Novartis AG (NYSE:NVS – Free Report) by 3.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,953,798 shares of the company’s stock after selling 79,242 shares during the period. Novartis accounts for about 2.8% of Cullen Capital Management LLC’s portfolio, making the stock its 2nd largest position. Cullen Capital Management LLC owned 0.10% of Novartis worth $278,553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently added to or reduced their stakes in NVS. First Financial Bankshares Inc boosted its position in Novartis by 1.4% in the 3rd quarter. First Financial Bankshares Inc now owns 237,542 shares of the company’s stock valued at $33,866,000 after buying an additional 3,227 shares during the period. HighTower Advisors LLC increased its position in shares of Novartis by 0.9% during the third quarter. HighTower Advisors LLC now owns 270,194 shares of the company’s stock worth $38,522,000 after acquiring an additional 2,373 shares during the period. Thoroughbred Financial Services LLC increased its position in shares of Novartis by 9.7% during the third quarter. Thoroughbred Financial Services LLC now owns 3,439 shares of the company’s stock worth $490,000 after acquiring an additional 305 shares during the period. Meramec Financial Planners LLC increased its position in shares of Novartis by 9.7% during the third quarter. Meramec Financial Planners LLC now owns 1,704 shares of the company’s stock worth $243,000 after acquiring an additional 150 shares during the period. Finally, IFG Advisory LLC raised its stake in shares of Novartis by 12.2% during the third quarter. IFG Advisory LLC now owns 2,618 shares of the company’s stock valued at $373,000 after acquiring an additional 284 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Bank of America reiterated a “buy” rating on shares of Novartis in a report on Tuesday, September 8th. Deutsche Bank downgraded Novartis from a “hold” rating to a “sell” rating in a report on Friday, October 30th. The Goldman Sachs Group reiterated a “sell” rating on shares of Novartis in a report on Monday, September 21st. Jefferies Financial Group reissued a “neutral” rating on shares of Novartis in a research report on Thursday, July 23rd. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a research note on Wednesday, October 28th. Six investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $152.25.
View Our Latest Analysis on NVS
Novartis Trading Down 0.3%
NYSE:NVS opened at $160.02 on Tuesday. Novartis AG has a one year low of $123.24 and a one year high of $170.46. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.70 and a current ratio of 0.88. The firm has a market cap of $305.35 billion, a P/E ratio of 30.54, a P/E/G ratio of 2.93 and a beta of 0.40. The firm has a 50-day simple moving average of $149.13 and a 200-day simple moving average of $152.66.
Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.25 by $0.21. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.53 billion. During the same quarter in the prior year, the company earned $2.25 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Equities analysts anticipate that Novartis AG will post 9.10 EPS for the current fiscal year.
Novartis Company Profile
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Read More
- Five stocks we like better than Novartis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
